Par Pharmaceutical, a portfolio company of TPG, has filed for an IPO of up to $100 million. The company will list under the ticker PRX, however, it has not yet settled on which exchange will list its stock. Founded in 1978, Par is a generic drug provider, as well as a developer of proprietary pharmaceutical products. The company currently has more than 80 products available and nearly 120 awaiting regulatory approval. TPG initially backed the company in 2012, acquiring the company for approximately $1.9 billion in a public-to-private buyout.